Novavax stock soars

Novavax stock soars as FDA removes clinical hold on its COVID and influenza shot
The U.S. Food and Drug Administration (FDA) has lifted its hold on a late-stage trial for Novavax’s COVID-influenza combination and standalone flu vaccines, the company reported on Monday (NASDAQ:MNDY).
FDA Lifts Clinical Hold On Novavax COVID-19-Influenza Combo Vaccine Candidate; Stock Up
(RTTNews) - Novavax, Inc. (NVAX) Monday said the Food and Drug Administration or FDA has removed the clinical hold on its COVID-19-Influenza Combination (CIC) and stand-alone influenza vaccine candidates. Novavax shares were up more than 13 percent in pre-market.
US FDA lifts clinical hold on Novavax's combo COVID-flu shot
The U.S. Food and Drug Administration has lifted its clinical hold on a late-stage trial of Novavax's COVID-influenza and its standalone flu vaccines after a safety concern was found to be unrelated to the combination shot,
Novavax Gets FDA Approval To Resume Testing Two Vaccines After Clinical Hold
Novavax said the Food and Drug Administration allowed it to continue testing a combination COVID-19-flu and standalone flu vaccine that had been put on hold.
Novavax to Move Forward With Covid-19-Flu Vaccine After FDA Lifts Clinical Hold -- Update
Novavax is already poised to benefit from a separate combined Covid-flu vaccine via a deal with Sanofi announed earlier this year. Under the $1.4 billion co-licensing agreement, announced in May, Sanofi will have the sole right to use Novavax's existing Covid-19 vaccine in combination with its own flu vaccine.
Novavax climbs as FDA lifts clinical hold on Covid, flu combo trials
Novavax (NVAX) shares surge 12% as FDA lifts clinical hold on COVID-19-Influenza Combination vaccine candidates.
Reuters3h
Novavax cuts 2024 revenue forecast again on lower COVID vaccine sales
Nov 12 (Reuters) - Novavax (NVAX.O), opens new tab cut its annual revenue forecast on Tuesday, citing lower-than-expected ...
Novavax Lowers 2024 Forecast Despite Q3 Revenue Beat, Stock Falls
Novavax reports Q3 2024 sales of $84.5 million, beating estimates, with a net loss of $121 million. EPS improves, FDA ...
Novavax falls after guidance cut on lower vaccine sales
Novavax (NVAX) stock falls 12% in premarket as company cuts full-year revenue guidance due to a lower sales outlook for its ...
Tennessean13d
Moderna, Pfizer or Novavax? How the three Covid-19 vaccines differ according to Yale Medicine
There are three types of vaccines available in the United States — Pfizer-BioNTech, Moderna and Novavax ... was the first COVID vaccine to receive FDA Emergency Use Authorization from the ...
NBC Bay Area18d
Fact Check: Q&A on the 2024-2025 COVID-19 Vaccines
(The Novavax vaccine works in a similar way to the mRNA vaccines — it just skips the step of having cells make spike protein, since the vaccine itself contains protein.) The company did not ...
WGN Radio20d
Why the FDA is holding production of Novavax COVID-Flu vaccines
Dr. Marty discusses why the FDA put a hold on the Novavax COVID-Flu vaccines and how their COVID vaccine is different from the others that are offered. She also explains the possible ...
Why Is COVID-19 Vaccine Maker Novavax Stock Trading Lower On Wednesday?
Novavax ends UK COVID-19 vaccine contract, agreeing to repay $123.8M in quarterly installments by 2027 as part of settlement.
Yahoo Finance27d
Novavax Studies for Flu, Covid Vaccines on Hold Over Safety
(Bloomberg) -- Novavax Inc. shares fell 19% after US regulators placed a hold on the company’s experimental vaccines because a study volunteer developed a serious nerve disorder. The pause ...